Inmune Bio (INMB) FCF Margin (2021 - 2025)
Inmune Bio (INMB) posted FCF Margin of 13648.0% for Q1 2025, up 74.44% sequentially from 53400.0% in Q1 2024, and up 3975200.0% YoY from N/an in Q1 2024.
Inmune Bio (INMB) FCF Margin (2021 - 2025) Analysis & Trends
Inmune Bio has reported FCF Margin for 5 years, with the latest figure at 13648.0% in Q1 2025.
- Quarterly FCF Margin rose 3975200.0% year-over-year to 13648.0% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 45872.0% (up 19269943.0% YoY) and the FY2025 annual result came in at 47284.0%, up 19128743.0% from the prior year.
- FCF Margin improved to 13648.0% in Q1 2025 per INMB's latest filing, from 53400.0% in the prior quarter.
- Over five years, FCF Margin peaked at 3002.63% in Q1 2023 and troughed at 127300.0% in Q1 2021.
- A 5-year average of 25651.3% and a median of 9916.28% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin jumped 12186135 bps in 2022, then tumbled 5039737 bps in 2024.
- Over 5 years, FCF Margin stood at 6000.0% in 2021, then gained by 2 bps to 5871.13% in 2022, then plunged by 108 bps to 12217.86% in 2023, then tumbled by 337 bps to 53400.0% in 2024, then soared by 74 bps to 13648.0% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 13648.0%, 53400.0%, and 12217.86% for Q1 2025, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -13,648.00% |
| Mar 31, 2024 | -53,400.00% |
| Dec 31, 2023 | -12,217.86% |
| Sep 30, 2023 | -9,916.28% |
| Jun 30, 2023 | -6,900.00% |
| Mar 31, 2023 | -3,002.63% |
| Dec 31, 2022 | -5,871.13% |
| Sep 30, 2022 | -3,435.71% |
| Jun 30, 2022 | -29,743.75% |
| Mar 31, 2022 | -5,438.65% |
| Dec 31, 2021 | -6,000.00% |
| Sep 30, 2021 | -56,592.86% |
| Mar 31, 2021 | -127,300.00% |